SecBot SecBot
SECBOTREPLAY Home › Report › CHRS

CHRS · Coherus reported Q3 2026 net revenue of $14.3M, up 23% YoY, and a…

Coherus Oncology, Inc. · PRESS-RELEASE filed Nov 9, 2026 at 16:06 ET

At the news

NEUTRALIMPACT 5/10

PRESS-RELEASE filed Nov 9, 2026 at 16:06 ET

Coherus reported Q3 2026 net revenue of $14.3M, up 23% YoY, and a non-GAAP net loss of $(0.20) per share, beating the consensus estimate of $(0.21). The company announced a strategic prioritization of tagmokitug in esophageal cancer, a ~30% headcount reduction, and guided to lower quarterly cash burn of $6M-$7M. Cash and equivalents fell to $83.6M from $172.1M at year-end 2025.

  • Q3 2026 net revenue $14.3M vs $11.6M YoY (+23%)
  • Non-GAAP EPS $(0.20) vs consensus $(0.21) (beat)
  • LOQTORZI net revenue $14.0M, up 25% YoY
  • Headcount reduction of ~30% to lower core cash burn by $6M-$7M quarterly

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access